Cargando…
Update on the therapy of adult-onset Still’s disease with a focus on IL-1-inhibition: a systematic review
INTRODUCTION: The past decade has seen increasingly rapid advances in understanding the pathogenic nature of adult-onset Still’s disease (AOSD) and its shared symptoms with the systemic juvenile idiopathic arthritis (sJIA). Interleukin-1 (IL-1) blocking agents are key elements in the treatment. In t...
Autores principales: | Kedor, Claudia, Tomaras, Stylianos, Baeumer, Daniel, Feist, Eugen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8641116/ https://www.ncbi.nlm.nih.gov/pubmed/34868356 http://dx.doi.org/10.1177/1759720X211059598 |
Ejemplares similares
-
Adult-Onset Still’s Disease: Clinical Aspects and Therapeutic Approach
por: Tomaras, Stylianos, et al.
Publicado: (2021) -
Distinct Effects of Interleukin-1β Inhibition upon Cytokine Profile in Patients with Adult-Onset Still’s Disease and Active Articular Manifestation Responding to Canakinumab
por: Ghannam, Khetam, et al.
Publicado: (2021) -
Adult-Onset Still’s Disease
por: Mitrovic, Stéphane, et al.
Publicado: (2019) -
Mechanisms, biomarkers and targets for adult-onset Still’s disease
por: Feist, Eugen, et al.
Publicado: (2018) -
Canakinumab for Treatment of Adult-Onset Still’s Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial
por: Kedor, Claudia, et al.
Publicado: (2020)